Adherence
High cost or insurance-related barriers are the primary drivers of discontinuation for obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice, accounting for nearly half of all early and late discontinuations.
If you are stopping semaglutide or tirzepatide, the most likely reason is cost or insurance issues, not that the drug didn't work. Check your insurance coverage, look for manufacturer coupons, and talk to your doctor about financial assistance programs before assuming the treatment is unsuitable for you.
Overall, 137 patients (47.6%) discontinued their medication due to cost or insurance- related issues... High cost or insurance- related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for obesity.
Why this rating
Large, real-world observational study with manual chart review and high inter-rater reliability, though limited to one health system.
Source
Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice
Hamlet Gasoyan et al. · Obesity · 2025
DOI 10.1002/oby.70058
Related findings · Adherence
- Regular physical activity (at least 150 minutes/week of moderate-intensity) reduces all-cause and cardiovascular mortality by 20-30% and lowers the risk of type 2 diabetes by 25-35%.Strong
- Increasing physical activity from a sedentary lifestyle to an active one in middle adulthood significantly reduces the risk of coronary events compared to remaining sedentary.Strong
- Resistance exercise is the only intervention capable of consistently restoring muscle function and strength in sarcopenia, partially overcoming age-related anabolic resistance.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →